Syndesi Therapeutics
Latest round
- Series A
Last raised
- Jun 2020
Total raised
- $27M
Investors
- 9
About Syndesi Therapeutics
Based in Belgium, and founded in 2018, Syndesi Therapeutics SA operates as a biotechnology company that develops SV2A modulators to improve cognition in diseases such as Alzheimer’s Disease, other dementias, and cognitive impairment associated with schizophrenia. In March 2022, AbbVie acquired Syndesi Therapeutics SA from Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation, etc for USD 1 billion in total deal value with USD 130 million upfront and additional contingent payments of up to USD 870 million based on the achievement of certain predetermined milestones. As of May 2023, Jonathan Savidge is the Chief Executive Officer (CEO). Syndesi Therapeutics SA creates medications for the treatment of neurological disorders such as Alzheimer's. The company's drugs have the ability to regulate the synaptic vesicle protein, which allows neurons in the brain to communicate with one another. As a result, healthcare providers can treat these cognitive diseases effectively by utilizing the appropriate therapy provided by this company.
Who invested in Syndesi Therapeutics
9 investors across 2 rounds
See all investors in Syndesi Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Syndesi Therapeutics
Who invested in Syndesi Therapeutics?
Syndesi Therapeutics has 9 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Syndesi Therapeutics raised?
Syndesi Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Syndesi Therapeutics last raise money?
Syndesi Therapeutics's most recent round on record is a Series A, in Jun 2020.
What does Syndesi Therapeutics do?
Based in Belgium, and founded in 2018, Syndesi Therapeutics SA operates as a biotechnology company that develops SV2A modulators to improve cognition in diseases such as Alzheimer’s Disease, other dementias, and cognitive impairment associated with schizophrenia.
Where is Syndesi Therapeutics headquartered?
Syndesi Therapeutics is headquartered in Louvain-la-Neuve, Belgium.
Which VCs invest in companies like Syndesi Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Syndesi Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Syndesi Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.